Evidence map›Paper›PMID 38721309›Full record

ArticleActa biochimica Polonica2024

Prevalence of circulating antibodies against hemagglutinin of influenza viruses in epidemic season 2021/2022 in Poland.

Katarzyna Kondratiuk, Ewelina Hallmann, Karol Szymański, Katarzyna Łuniewska, Anna Poznańska, Lidia B Brydak

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta biochimica Polonica, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Katarzyna KondratiukLaboratory of Influenza Viruses and Respiratory Viruses, Department of Virology, National Institute of Public Health NIH-National Research Institute, Warsaw, Poland.
Ewelina HallmannLaboratory of Influenza Viruses and Respiratory Viruses, Department of Virology, National Institute of Public Health NIH-National Research Institute, Warsaw, Poland.
Karol SzymańskiLaboratory of Influenza Viruses and Respiratory Viruses, Department of Virology, National Institute of Public Health NIH-National Research Institute, Warsaw, Poland.
Katarzyna ŁuniewskaLaboratory of Influenza Viruses and Respiratory Viruses, Department of Virology, National Institute of Public Health NIH-National Research Institute, Warsaw, Poland.
Anna PoznańskaDepartment of Population Health Monitoring and Analysis, National Institute of Public Health NIH-National Research Institute, Warsaw, Poland.
Lidia B BrydakLaboratory of Influenza Viruses and Respiratory Viruses, Department of Virology, National Institute of Public Health NIH-National Research Institute, Warsaw, Poland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The aim of the study was to determine the level of anti-hemagglutinin antibodies in the serum of patients during the 2021/2022 epidemic season in Poland. A total of 700 sera samples were tested, divided according to the age of the patients into 7 age groups: 0-4 years of age, 5-9 years of age, 10-14 years of age, 15-25 years of age, 26-44 years of age, 45-64 years of age and ≥65 years of age, 100 samples were collected from each age group. Anti-hemagglutinin antibody levels was determined using the haemagglutination inhibition assay (OZHA). The results obtained confirm the presence of anti-hemagglutinin antibodies for the antigens A/Victoria/2570/2019 (H1N1) pdm09, A/Cambodia/e0826360/2020 (H3N2), B/Washington/02/2019 and B/Phuket/3073/2013 recommended by World Health Organization (WHO) for the 2021/2022 epidemic season. The analysis of the results shows differences in the levels of individual anti-hemagglutinin antibodies in the considered age groups. In view of very low percentage of the vaccinated population in Poland, which was 6.90% in the 2021/2022 epidemic season, the results obtained in the study would have to be interpreted as the immune system response in patients after a previous influenza virus infection.

Indexed as

Antibodies, ViralHemagglutinin Glycoproteins, Influenza VirusInfluenza A Virus, H1N1 SubtypeInfluenza A Virus, H3N2 SubtypeInfluenza, HumanAdolescentAdultAgedChildChild, PreschoolEpidemicsFemaleHemagglutination Inhibition TestsHumansInfantInfant, NewbornAntibodies, ViralHemagglutinin Glycoproteins, Influenza VirusGMThemagglutinin antibodiesinfluenzaprotection rateserum financial support

Identifiers

PMID38721309
PMCPMC11077356

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.